NOXXON – HALF-YEARLY REPORT ON THE LIQUIDITY AGREEMENT WITH INVEST SECURITIES

Berlin – NOXXON Pharma SA (Euronext Growth Paris: ALNOX), a biotechnology company specializing in improving cancer treatments by targeting the tumor microenvironment (TME), announces today that pursuant to the liquidity contract awarded to Invest in securities through NOXXON Pharma SA the following assets appeared in the liquidity account.

From December 31, 2021

Number of shares: 59,951

Liquidity account cash balance: €26,132.73

Contact:

Tel: +49 (0) 30 726247 0

Email: [email protected]

About NOXXON

NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and cancer immunity cycle by breaking down the tumor protective barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program, NOX-A12, has provided final data from a combined Keytruda trial in patients with metastatic colorectal and pancreatic cancer, published at the ESMO conference in September 2020 and in July 2021 the company announced its Phase 2 study, OPTIMUS, to further evaluate the safety and efficacy of NOX-A12 in combination with Merck‘s Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiation therapy, which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers.

GLORIA, a trial of NOX-A12 in combination with radiation therapy in newly diagnosed brain cancer patients who will not clinically benefit from standard chemotherapy, has provided interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. Additionally, GLORIA was extended to assess the benefit of NOX-A12 with other treatment combinations, radiotherapy + bevacizumab and radiotherapy + pembrolizumab. The Company’s second clinical-stage asset, NOX-E36, is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors.

About the GLORIA study

GLORIA (NCT04121455) is NOXXON’s dose-escalating Phase 1/2 study of NOX-A12 in combination with radiation in first-line patients with partially resected or unresected glioblastoma (brain cancer) with a promoter Unmethylated MGMT (resistant to standard chemotherapy). GLORIA is further evaluating the safety and efficacy of NOX-A12 in three additional arms combining NOX-A12 with: A. radiation therapy in patients with complete tumor resection; B. radiation therapy and bevacizumab in patients with incomplete tumor resection and C. radiation therapy and pembrolizumab in patients with incomplete tumor resection.

About the OPTIMUS study

OPTIMUS (NCT04901741) is NOXXON’s open-label, two-arm Phase 2 study of NOX-A12 plus pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in patients with stable microsatellite metastatic pancreatic cancer.

Warning

Certain statements in this communication contain formulations or terms that refer to future or future developments, as well as negations of these formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information contained in this communication regarding expected or future results of business segments, financial indicators, changes in financial condition or other financial or statistical data contains such forward-looking statements. The company cautions potential investors not to rely on these forward-looking statements as certain predictions of actual future events and developments.